STAMPEDE investigators, Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', Lancet Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1 Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
James, N D, Ingleby, F C, Clarke, N W, Amos, C L, Attard, G, Brawley, C D, Chowdhury, S, Cross, W, Dearnaley, D P, Gilbert, D C, Gillessen, S, Jones, R J, Langley, R E, Macnair, A, Malik, Z I, Mason, M D, Matheson, D J, Millman, R, Parker, C C, Rush, H L, Russell, J M, Au, C, Ritchie, A W S, Mestre, R P, Ahmed, I, Birtle, A J, Brock, S J, Das, P, Ford, V A, Gray, E K, Hughes, R J, Manetta, C B, McLaren, D B, Nikapota, A D, O'Sullivan, J M, Perna, C, Peedell, C, Protheroe, A S, Sundar, S, Tanguay, J S, Tolan, S P, Wagstaff, J, Wallace, J B, Wylie, J P, Zarkar, A, Parmar, M K B & Sydes, M R 2022, ' Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial ', JNCI Cancer Spectrum, vol. 6, no. 4, pkac043 . https://doi.org/10.1093/jncics/pkac043
Wong, C, Dakin, R S, Williamson, J, Newton, J, Steven, M, Colville, S, Stavrou, M, Gregory, J M, Elliott, E, Mehta, A R, Chataway, J, Swingler, R J, Parker, R A, Weir, C J, Stallard, N, Parmar, M K B, Macleod, M R, Pal, S & Chandran, S 2022, ' Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease ', BMJ Open, vol. 12, no. 7, pp. e064173 . https://doi.org/10.1136/bmjopen-2022-064173